IN
Inovio Pharmaceuticals, Inc.
INO · NASDAQ
$1.24 +2.48% (+$0.03)
1M -0.80%
Market Cap $85.7M
P/E Ratio -
Div. Yield -
ROE 1,005.80%
Bulios Fair Price
$1.02
17.7% downside
Current Price
$1.24
Undervalued Fair Value Overvalued
According to Bulios Fair Price, INO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
0/9Valuation
0 /100
Expensive P/B 19.60x
EV/FFO N/A
P/E N/A
Growth
0 /100
Declining Book val. growth 52.32%
Rev. growth 81.47%
FCF growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 136.52%
ROIC 640.60%
Asset turnover 0.00x
Debt
28 /100
High Current ratio 1.00x
Debt/Equity 1.83x
Debt/Assets N/A
Stability
62 /100
Moderate EPS volatility 11.79%
Beta 1.63x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about INO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jacqueline E. Shea
Employees
112
Headquarters
Plymouth Meeting
Upcoming events
10 NOV
Earnings
Upcoming earnings report